Menu
ncarol.com
  • Home
  • Business
  • Health
  • Books
  • Non-profit
  • Financial
  • Transportation
  • Real Estate
  • Education
ncarol.com

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
ncarol.com/10212254

Trending...
  • Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
  • Beatrice Thompson to Be Inducted into the Order of the Trojan
  • Elliott Expands Investment Services with Naviark App Launch
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

More on ncarol.com
  • Podcast for Midlife Women Entrepreneurs Celebrates 100th Episode with Rhea Lana's Founder and CEO
  • What If Help Could Come Before the Fall?
  • Record-Breaking BBQ Bash and GolfFest Ignite Two States
  • OddsTrader Examines the NHL Presidents Trophy Curse: Why Regular-Season Success Rarely Leads to Playoff Glory
  • Bookmakers Review Launches Betting Insights on NBC's "The Voice: Battle of Champions"

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Investor Contact:

Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Grammy award-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole"
  • Thread Advisory Group Launches to Help Retailers Turn Strategy Into Lasting Results
  • QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI
  • New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
  • Meet the Dentist Bringing Advanced, Compassionate Care to the Kernersville Community
  • Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
  • Belligerent Lifestyle Apparel Skate Team Set to Compete at the 31st Annual Tampa Am
  • White Glove Restoration Sends "Help in Boxes" to Support Communities in Ghana
  • NASA Agreements, New Ocean Exploration Applications Added to Partnerships with Defiant Space Corp and Emtel Energy USA for Solar Tech Leader: $ASTI
  • Chic and Secure: The Blue Luna Debuts Stylish Keychains with Purpose
  • BEC Technologies Showcases Leadership in Private Broadband Ecosystem with Inclusion in UTC's Ecosystem Summary Report
  • $500,000 in Stock Dividend for Shareholders in 2025 Sweetens The Pot on Success of Becoming Debt Free with No Convertible Notes or Warrants for $IQST
  • Milwaukee Job Corps Center: Essential Workforce Training—Admissions Now Open
  • Aissist.io Launches Hybrid AI Workforce to Solve AI Pilot Failure for Customer Support Automation
  • Christy Sports Makes Snowsports More Accessible for Families to Get Outside Together
  • MainConcept Completes Management Buyout to Become Independent Company
  • LIB Industry Expands Full-Series Salt Spray Corrosion Test Chambers to Meet Global Testing Standards
  • The Easy Way to Collect Every Wedding Photo from Your Guests - No App Needed
  • REPRESENTATION REVOLUTION: FLM TV Network Launches as America's First Truly Diverse Broadcast Network
  • Soaps & Essentials Invites the Community to Help Spotlight Local Brand Making a Big Difference
_catLbl0 _catLbl1

Popular on ncarol.com

  • Open Art Call | The Art of Artificial Intelligence | Copenhagen - 101
  • Security Alert: TZNXG Warns Investors About "Fund Recovery" Scams
  • KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism
  • One Park Financial Earns Great Place to Work® Certification for the Eighth Time
  • Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
  • NIUFO Positions Platform for European Market Entry with MiCA-Aligned Infrastructure Development
  • Gemma's Hope Launches Hope Hour Gala to Raise Funds for Families Facing Pregnancy & Infant Loss
  • 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
  • Lake Norman Philharmonic Free Concert Opens 2025-2026 Season
  • Artists Find Serenity in Color

Similar on ncarol.com

  • Six-Figure Chicks Book Series 96 Authors, 6 Volumes Published to Empower and Mentor Women Nationwide
  • $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
  • Podcast for Midlife Women Entrepreneurs Celebrates 100th Episode with Rhea Lana's Founder and CEO
  • OddsTrader Examines the NHL Presidents Trophy Curse: Why Regular-Season Success Rarely Leads to Playoff Glory
  • Coming Up this Weekend on CNBC Mike Milligan Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • $73.6M Pipeline, $10M Crypto Play & Legal Firepower: Why Investors Are Watching Cycurion (N A S D A Q: CYCU) Like a Hawk
  • New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
  • NASA Agreements, New Ocean Exploration Applications Added to Partnerships with Defiant Space Corp and Emtel Energy USA for Solar Tech Leader: $ASTI
  • Chic and Secure: The Blue Luna Debuts Stylish Keychains with Purpose
  • $500,000 in Stock Dividend for Shareholders in 2025 Sweetens The Pot on Success of Becoming Debt Free with No Convertible Notes or Warrants for $IQST
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute